Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aksys

This article was originally published in The Gray Sheet

Executive Summary

Enrolls 24 patients in a six-month clinical study of its PHD personal hemodialysis system to support a future 510(k) submission to FDA. The three-phase trial is being conducted at dialysis clinics located in Washington, Missouri and Mississippi

You may also be interested in...



Aksys

Firm raises $11.8 mil. in a private placement of 1.5 mil. shares to institutional investors. Lincolnshire, Illinois-based Aksys is conducting clinical trials of its PHD personal hemodialysis system and expects to submit a 510(k) by the end of October (1"The Gray Sheet" Jan. 10, In Brief). Proceeds will support pre-commercialization activities, including a planned ramp-up in sales staff and manufacturing. U.S. Bancorp Piper Jaffray was placement agent for the financing

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel